These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7551252)

  • 21. Identification of HLA-A*0201/-A*2402-restricted CTL epitope-peptides derived from a novel cancer/testis antigen, MCAK, and induction of a specific antitumor immune response.
    Kawamoto M; Tanaka F; Mimori K; Inoue H; Kamohara Y; Mori M
    Oncol Rep; 2011 Feb; 25(2):469-76. PubMed ID: 21165574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on vaccine development in AIDS and cancer.
    MacDougall DS
    J Int Assoc Physicians AIDS Care; 1995 Apr; 1(3):18-24. PubMed ID: 11362485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Roles of heat-shock proteins in innate and adaptive immunity.
    Srivastava P
    Nat Rev Immunol; 2002 Mar; 2(3):185-94. PubMed ID: 11913069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune surveillance and immunotherapy: lessons from carbohydrate mimotopes.
    Pashov A; Monzavi-Karbassi B; Kieber-Emmons T
    Vaccine; 2009 May; 27(25-26):3405-15. PubMed ID: 19200843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Current status of cancer management. 4. Possibility for cancer immunotherapy].
    Shiku H
    Nihon Naika Gakkai Zasshi; 1998 Sep; 87(9):1768-71. PubMed ID: 9816846
    [No Abstract]   [Full Text] [Related]  

  • 26. A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation.
    Hida N; Maeda Y; Katagiri K; Takasu H; Harada M; Itoh K
    Cancer Immunol Immunother; 2002 Jun; 51(4):219-28. PubMed ID: 12012109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumour immunology: false hopes--new horizons?
    Alexandroff AB; Robins RA; Murray A; James K
    Immunol Today; 1998 Jun; 19(6):247-50. PubMed ID: 9639986
    [No Abstract]   [Full Text] [Related]  

  • 28. Immunotherapy and immunity to cancer: cellular mechanisms.
    Ferrini S; Melioli G; Moretta L
    Curr Opin Immunol; 1989-1990; 2(5):683-8. PubMed ID: 2701967
    [No Abstract]   [Full Text] [Related]  

  • 29. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women.
    Rowland-Jones S; Sutton J; Ariyoshi K; Dong T; Gotch F; McAdam S; Whitby D; Sabally S; Gallimore A; Corrah T
    Nat Med; 1995 Jan; 1(1):59-64. PubMed ID: 7584954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How much help does a vaccine-induced T-cell response need?
    Weber JS; Mulé JJ
    J Clin Invest; 2001 Mar; 107(5):553-4. PubMed ID: 11238555
    [No Abstract]   [Full Text] [Related]  

  • 31. Generation of cellular immune responses to antigenic tumor peptides.
    Pietersz GA; Apostolopoulos V; McKenzie IF
    Cell Mol Life Sci; 2000 Feb; 57(2):290-310. PubMed ID: 10766024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The value of synthetic peptides as vaccines for eliciting T-cell immunity.
    Schwartz RH
    Curr Top Microbiol Immunol; 1986; 130():79-85. PubMed ID: 2946557
    [No Abstract]   [Full Text] [Related]  

  • 33. Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma.
    Minami T; Minami T; Shimizu N; Yamamoto Y; De Velasco M; Nozawa M; Yoshimura K; Harashima N; Harada M; Uemura H
    J Immunother; 2015 Sep; 38(7):285-91. PubMed ID: 26261892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
    Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
    J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiviral cytotoxic T lymphocyte induction and vaccination.
    Rouse BT; Norley S; Martin S
    Rev Infect Dis; 1988; 10(1):16-33. PubMed ID: 2451265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of infectious and neoplastic diseases with transfer factor.
    Kirkpatrick CH; Gallin JI
    Oncology; 1974; 29(1):46-73. PubMed ID: 4600778
    [No Abstract]   [Full Text] [Related]  

  • 37. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan.
    Apostolopoulos V; Pietersz GA; McKenzie IF
    Vaccine; 1996 Jun; 14(9):930-8. PubMed ID: 8843637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptide mimics of a tumor antigen induce functional cytotoxic T cells.
    Apostolopoulos V; Lofthouse SA; Popovski V; Chelvanayagam G; Sandrin MS; McKenzie IF
    Nat Biotechnol; 1998 Mar; 16(3):276-80. PubMed ID: 9528009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Naturally formed or artificially reconstituted non-covalent alpha2-macroglobulin-peptide complexes elicit CD91-dependent cellular immunity.
    Binder RJ; Kumar SK; Srivastava PK
    Cancer Immun; 2002 Dec; 2():16. PubMed ID: 12747761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
    Merritt RE; Yamada RE; Crystal RG; Korst RJ
    J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.